Evidence map›Paper›PMID 38828455›Full record

ArticleFrontiers in pharmacology2024

Benserazide, a cystathionine beta-synthase (CBS) inhibitor, potentially enhances the anticancer effects of paclitaxel via inhibiting the S-sulfhydration of SIRT1 and the HIF1-α/VEGF pathway.

Wei Zhao, Shasha Feng, Jian Wang, Zhenshuai Zhang, Lu Chen, Li Jiang, Ming Li, Tianxiao Wang

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Role of cystathionine-β-synthase and hydrogen sulfide in down syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei ZhaoSchool of Pharmacy, Henan University, Kaifeng, Henan, China.
Shasha FengSchool of Pharmacy, Henan University, Kaifeng, Henan, China.
Jian WangSchool of Pharmacy, Henan University, Kaifeng, Henan, China.
Zhenshuai ZhangSchool of Pharmacy, Henan University, Kaifeng, Henan, China.
Lu ChenSchool of Pharmacy, Henan University, Kaifeng, Henan, China.
Li JiangSchool of Pharmacy, Henan University, Kaifeng, Henan, China.
Ming LiSchool of Pharmacy, Henan University, Kaifeng, Henan, China.
Tianxiao WangSchool of Pharmacy, Henan University, Kaifeng, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer targeted therapy is essential to minimize damage to normal cells and improve treatment outcomes. The elevated activity of Cystathionine beta-synthase (CBS), an enzyme responsible for producing endogenous hydrogen sulfide (H

Indexed as

benserazidecancerHIF1-αpaclitaxelSIRT1VEGF

Identifiers

PMID38828455
PMCPMC11143879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.